Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.71 |
| ▸ | GOT1 | P17174 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.42 |
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | PI4KA | P42356 | 1/20 | 0.40 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.40 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.40 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.40 |
| ▸ | F12 | P00748 | 1/20 | 0.40 |
| ▸ | PLAU | P00749 | 1/20 | 0.40 |
| ▸ | NCF1 | P14598 | 1/20 | 0.40 |
| ▸ | NOS3 | P29474 | 1/20 | 0.40 |
| ▸ | NOS1 | P29475 | 1/20 | 0.40 |
| ▸ | NOS2 | P35228 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31416835 | 0.84 | KDM4E (1.00) | KDM4EKMT2AALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL345211 | 0.84 | GOT1 (0.62) | KDM4EGOT1MEN1KMT2AGFER | |
| SCHEMBL221530 | 0.84 | KDM4E (1.00) | KDM4EKMT2AALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL29365992 | 0.84 | GOT1 (0.62) | KDM4EGOT1MEN1KMT2AGFER | |
| SCHEMBL24575366 | 0.74 | IMPDH2 (0.43) | KDM4EGOT1LMNAPOLBHTT | |
| SCHEMBL30771962 | 0.74 | IMPDH2 (0.43) | KDM4EGOT1MAPTRAB9ALMNA | |
| SCHEMBL24575364 | 0.74 | IMPDH2 (0.43) | KDM4EGOT1MAPTRAB9ALMNA | |
| Bicarbonate SCHEMBL11022555 | 0.73 | GOT1 (0.52) | KDM4EGOT1MEN1KMT2AGFER | |
| SCHEMBL2306302 | 0.71 | MEN1 (0.50) | KDM4EGOT1MEN1KMT2AGFER | |
| SCHEMBL2126344 | 0.71 | GOT1 (0.50) | KDM4EGOT1MEN1KMT2AGFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4496727-A | ORGANIC PIGMENTS; PLASTICS; LACQUERS; INKS; COATINGS; COLOR FASTNESS | CIBA-GEIGY CORPORATION (US) | 1985-01-29 | — | — | US | claimed |
| US-4385174-A | FOR PIGMENTS | CIBA-GEIGY CORPORATION (US) | 1983-05-24 | — | — | US | claimed |
| WO-2025036275-A1 | NLRP3 INFLAMMASOME INHIBITOR AND USE THEREOF | 药捷安康(南京)科技股份有限公司 | 2025-02-20 | — | — | WO | disclosed |
| CN-119462517-A | NLRP3 inflammation corpuscle inhibitor and application thereof | 药捷安康(南京)科技股份有限公司 | 2025-02-18 | — | — | CN | disclosed |
| US-20240294542-A1 | NLRP3 INFLAMMASOME INHIBITOR AND APPLICATION THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2024-09-05 | — | — | US | disclosed |
| CN-112707908-B | Organic electronic material and application thereof | 北京鼎材科技有限公司 | 2024-03-15 | — | — | CN | disclosed |
| CN-117624171-A | Organic electronic material and application thereof | 北京鼎材科技有限公司 | 2024-03-01 | — | — | CN | disclosed |
| WO-2023131277-A1 | NLRP3 INFLAMMASOME INHIBITOR AND USES THEREOF | 药捷安康(南京)科技股份有限公司 | 2023-07-13 | — | — | WO | disclosed |
| WO-2023275366-A1 | NLRP3 INFLAMMASOME INHIBITORS | ASTRAZENECA AB (SE) | 2023-01-05 | — | — | WO | disclosed |
| WO-2023278438-A1 | NLRP3 MODULATORS | ZOMAGEN BIOSCIENCES LTD (US) | 2023-01-05 | — | — | WO | disclosed |
| WO-2022253326-A1 | NLRP3 INFLAMMASOME INHIBITOR AND APPLICATION THEREOF | 药捷安康(南京)科技股份有限公司 | 2022-12-08 | — | — | WO | disclosed |
| EP-1745039-A4 | 3-ARYL-5,6-DISUBSTITUTED PYRIDAZINES | NEUROGEN CORP (US) | 2009-07-22 | — | — | EP | disclosed |
| WO-2008110611-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2008-09-18 | — | — | WO | disclosed |
| US-20070213338-A1 | Triazolo-Pyridazine Compounds and Derivatives Thereof Useful in the Treatment of Neuropathic Pain | MERCK & CO., INC. | 2007-09-13 | — | — | US | disclosed |
| CN-1984904-A | 3-aryl-5,6-disubstituted pyridazines | NEUROGEN CORP (US) | 2007-06-20 | — | — | CN | disclosed |
| EP-1745039-A2 | 3-ARYL-5,6-DISUBSTITUTED PYRIDAZINES | Neurogen Corporation (US) | 2007-01-24 | — | — | EP | disclosed |
| CN-1871008-A | Triazolo-pyridazine compounds and derivatives thereof useful in the treatment of neuropathic pain | MERCK & CO INC (US) | 2006-11-29 | — | — | CN | disclosed |
| WO-2006004589-A2 | 3-ARYL-5,6-DISUBSTITUTED PYRIDAZINES | NEUROGEN CORPORATION (US) | 2006-01-12 | — | — | WO | disclosed |
| US-4496727-A | ORGANIC PIGMENTS; PLASTICS; LACQUERS; INKS; COATINGS; COLOR FASTNESS | CIBA-GEIGY CORPORATION (US) | 1985-01-29 | — | — | US | disclosed |
| US-4385174-A | FOR PIGMENTS | CIBA-GEIGY CORPORATION (US) | 1983-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240294542-A1 | NLRP3 INFLAMMASOME INHIBITOR AND APPLICATION THEREOF | NLRP3, NLRP1, PYCARD | KDM4E 3867/4885GOT1 534/4885MEN1 4031/4885 |
| US-20070213338-A1 | Triazolo-Pyridazine Compounds and Derivatives Thereof Useful in the Treatment of Neuropathic Pain | PER2, CNR2, OPRD1 | KDM4E 1349/4885GOT1 3789/4885MEN1 4543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.